In: Clinical Infectious Diseases, 2011, vol. 53, no. 11, p. 1130-1139
|
In: The Journal of Infectious Diseases, 2015, vol. 212, no. 1, p. 28-38
|
In: Clinical Infectious Diseases, 2009, vol. 48, no. 2, p. 239-247
|
In: Clinical Infectious Diseases, 2007, vol. 44, no. 1, p. 94-102
|
In: The Journal of Infectious Diseases, 2013, vol. 208, no. 7, p. 1102-1112
|
In: Clinical Infectious Diseases, 2005, vol. 41, no. 3, p. 361-372
|
In: Clinical Infectious Diseases, 2008, vol. 46, no. 5, p. 761-767
|
In: Clinical Infectious Diseases, 2011, vol. 52, no. 4, p. 532-539
|
In: Clinical Infectious Diseases, 2014, vol. 58, no. 2, p. 285-294
|
In: Neurology, 2013, vol. 80, no. 6, p. 553–560
Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by placebo...
|